{"id":"NCT03308968","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"An Efficacy and Safety Study of Fremanezumab in Adults With Migraine","officialTitle":"A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-10-13","primaryCompletion":"2018-10-02","completion":"2019-05-29","firstPosted":"2017-10-13","resultsPosted":"2019-10-09","lastUpdate":"2021-11-09"},"enrollment":838,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine Prophylaxis"],"interventions":[{"type":"DRUG","name":"Fremanezumab","otherNames":["TEV-48125"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Fremanezumab Quarterly","type":"EXPERIMENTAL"},{"label":"Fremanezumab Monthly","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy, safety, and tolerability of monthly and quarterly subcutaneous (sc) injections of fremanezumab compared with sc injections of placebo in participants with chronic migraine (CM) or episodic migraine (EM) who have responded inadequately to 2 to 4 classes of prior preventive treatments.\n\nApproximately equal numbers of participants from each subgroup (CM and EM) are randomized in blinded-fashion 1:1:1 into one of 3 treatments for the subgroup - 2 active treatments and 1 placebo treatment- consisting of monthly injections for 3 months (up to Week 12). Then all participants continue into an open-label extension of 3 months (up to Week 24) during which everyone is administered sc injections of fremanezumab.","primaryOutcome":{"measure":"DB Period: Change From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Fremanezumab","timeFrame":"Baseline (Day -28 to Day -1), up to Week 12","effectByArm":[{"arm":"Placebo","deltaMin":-0.6,"sd":0.34},{"arm":"Fremanezumab Quarterly","deltaMin":-3.7,"sd":0.34},{"arm":"Fremanezumab Monthly","deltaMin":-4.1,"sd":0.34}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":113,"countries":["United States","Belgium","Czechia","Denmark","Finland","France","Germany","Italy","Netherlands","Poland","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["36038833","35331009","35302681","34922436","34819017","34246226","33990144","33863272","31427046"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":277},"commonTop":["Injection site erythema","Nasopharyngitis","Injection site induration","Migraine","Injection site pain"]}}